Biotron Ltd
BIT
Company Profile
Business description
Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.
Contact
66 Hunter Street
Level 2
SydneyNSW2000
AUST: +61 293003344
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
4
Stocks News & Analysis
stocks
Cheap Dividend Aristocrat has Fair Value raised after earnings
Dividend forecasts raised after balance sheet regains strength.
stocks
Why great earnings haven't been good enough for AI hardware stocks
Stocks that had been posting triple-digit returns are sliding on earnings results.
stocks
Fair Value increased for Big 4 bank after earnings
Shares still overvalued, with analysts thinking the fundamentals no longer matter to the share price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,316.30 | 16.50 | -0.18% |
| CAC 40 | 8,650.56 | 24.38 | -0.28% |
| DAX 40 | 26,299.74 | 31.33 | -0.12% |
| Dow JONES (US) | 53,839.99 | 69.72 | 0.13% |
| FTSE 100 | 10,772.67 | 60.48 | -0.56% |
| HKSE | 25,195.55 | 200.96 | -0.79% |
| NASDAQ | 26,803.03 | 214.54 | 0.81% |
| Nikkei 225 | 68,808.35 | 499.76 | 0.73% |
| NZX 50 Index | 13,836.24 | 10.94 | 0.08% |
| S&P 500 | 7,798.99 | 50.49 | 0.65% |
| S&P/ASX 200 | 9,119.60 | 15.50 | -0.17% |
| SSE Composite Index | 3,921.25 | 5.71 | -0.15% |